» Articles » PMID: 7550349

The Carrier Frequency of the BRCA1 185delAG Mutation is Approximately 1 Percent in Ashkenazi Jewish Individuals

Overview
Journal Nat Genet
Specialty Genetics
Date 1995 Oct 1
PMID 7550349
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Since BRCA1, the first major gene responsible for inherited breast cancer, was cloned, more than 50 unique mutations have been detected in the germline of individuals with breast and ovarian cancer. In high-risk pedigrees, female carriers of BRCA1 mutations have an 80-90% lifetime risk of breast cancer, and a 40-50% risk of ovarian cancer. However, the mutation stats of individuals unselected for breast or ovarian cancer has not been determined, and it is not known whether mutations in such individuals confer the same risk of cancer as in individuals from the high-risk families studied so far. Following the finding of a 185delAG frameshift mutation in several Ashkenazi Jewish breast/ovarian families, we have determined the frequency of this mutation in 858 Ashkenazim seeking genetic testing for conditions unrelated to cancer, and in 815 reference individuals not selected for ethnic origin. We observed the 185delAG mutation in 0.9% of Ashkenazim (95% confidence limit, 0.4-1.8%) and in none of the reference samples. Our results suggest that one in a hundred women of Ashkenazi descent may be at especially high risk of developing breast and/or ovarian cancer.

Citing Articles

Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer.

Weddle C, Blancard M, Uche N, Pongpamorn P, Cejas R, Burridge P NPJ Precis Oncol. 2025; 9(1):53.

PMID: 40000798 PMC: 11862011. DOI: 10.1038/s41698-025-00837-5.


Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017.

Wei Y, Ning L, Xu Y, Ma J, Li D, Feng Z EClinicalMedicine. 2024; 79:102983.

PMID: 39720606 PMC: 11667631. DOI: 10.1016/j.eclinm.2024.102983.


Molecular analysis of BRCA1 and BRCA2 genes in La Rioja (Spain): five new variants.

Salazar Saez R, Zorrilla M, Sanchez R, Cebollero A, Manrique I, Martin A Hered Cancer Clin Pract. 2024; 22(1):22.

PMID: 39438962 PMC: 11495111. DOI: 10.1186/s13053-024-00296-2.


Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib.

Afrasanie V, Rusu A, Gheorghe A, Froicu E, Dumitrescu E, Gafton B Diagnostics (Basel). 2024; 14(17).

PMID: 39272683 PMC: 11394373. DOI: 10.3390/diagnostics14171898.


High Frequency of BRCA2 c.5576_5579del Carriers in Kakogawa, Japan.

Nakamura H, Mizumoto S, Tanino H, Niwa Y, Ogino M, Sakoda Y Cancer Diagn Progn. 2024; 4(3):309-314.

PMID: 38707742 PMC: 11062150. DOI: 10.21873/cdp.10325.